214 related articles for article (PubMed ID: 25015418)
41. miR-187-3p inhibits the metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting S100A4.
Dou C; Liu Z; Xu M; Jia Y; Wang Y; Li Q; Yang W; Zheng X; Tu K; Liu Q
Cancer Lett; 2016 Oct; 381(2):380-90. PubMed ID: 27544906
[TBL] [Abstract][Full Text] [Related]
42. Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma.
Lingala S; Cui YY; Chen X; Ruebner BH; Qian XF; Zern MA; Wu J
Exp Mol Pathol; 2010 Aug; 89(1):27-35. PubMed ID: 20511115
[TBL] [Abstract][Full Text] [Related]
43. Oxytetracycline have the therapeutic efficiency in CD133
Song Y; Kim IK; Choi I; Kim SH; Seo HR
Sci Rep; 2018 Oct; 8(1):16100. PubMed ID: 30382122
[TBL] [Abstract][Full Text] [Related]
44. Positive correlation of Oct4 and ABCG2 to chemotherapeutic resistance in CD90(+)CD133(+) liver cancer stem cells.
Jia Q; Zhang X; Deng T; Gao J
Cell Reprogram; 2013 Apr; 15(2):143-50. PubMed ID: 23438193
[TBL] [Abstract][Full Text] [Related]
45. Ultrasound-targeted microbubble destruction-mediated downregulation of CD133 inhibits epithelial-mesenchymal transition, stemness and migratory ability of liver cancer stem cells.
Liu YM; Li XF; Liu H; Wu XL
Oncol Rep; 2015 Dec; 34(6):2977-86. PubMed ID: 26370320
[TBL] [Abstract][Full Text] [Related]
46. BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocellular carcinoma.
Zhang L; Sun H; Zhao F; Lu P; Ge C; Li H; Hou H; Yan M; Chen T; Jiang G; Xie H; Cui Y; Huang X; Fan J; Yao M; Li J
Cancer Res; 2012 Aug; 72(16):4276-85. PubMed ID: 22773665
[TBL] [Abstract][Full Text] [Related]
47. miR-342-3p affects hepatocellular carcinoma cell proliferation via regulating NF-κB pathway.
Zhao L; Zhang Y
Biochem Biophys Res Commun; 2015 Feb; 457(3):370-7. PubMed ID: 25580008
[TBL] [Abstract][Full Text] [Related]
48. Dynamic imbalance between cancer cell subpopulations induced by transforming growth factor beta (TGF-β) is associated with a DNA methylome switch.
Martin M; Ancey PB; Cros MP; Durand G; Le Calvez-Kelm F; Hernandez-Vargas H; Herceg Z
BMC Genomics; 2014 Jun; 15(1):435. PubMed ID: 24898317
[TBL] [Abstract][Full Text] [Related]
49. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.
Ma S; Lee TK; Zheng BJ; Chan KW; Guan XY
Oncogene; 2008 Mar; 27(12):1749-58. PubMed ID: 17891174
[TBL] [Abstract][Full Text] [Related]
50. Androgen receptor (AR)/miR-520f-3p/SOX9 signaling is involved in altering hepatocellular carcinoma (HCC) cell sensitivity to the Sorafenib therapy under hypoxia via increasing cancer stem cells phenotype.
Xiao Y; Sun Y; Liu G; Zhao J; Gao Y; Yeh S; Gong L; Chang C
Cancer Lett; 2019 Mar; 444():175-187. PubMed ID: 30448543
[TBL] [Abstract][Full Text] [Related]
51. Lipopolysaccharide supports maintaining the stemness of CD133(+) hepatoma cells through activation of the NF-κB/HIF-1α pathway.
Lai FB; Liu WT; Jing YY; Yu GF; Han ZP; Yang X; Zeng JX; Zhang HJ; Shi RY; Li XY; Pan XR; Li R; Zhao QD; Wu MC; Zhang P; Liu JF; Wei LX
Cancer Lett; 2016 Aug; 378(2):131-41. PubMed ID: 27208741
[TBL] [Abstract][Full Text] [Related]
52. Small regulatory polypeptide of amino acid response negatively relates to poor prognosis and controls hepatocellular carcinoma progression via regulating microRNA-5581-3p/human cardiolipin synthase 1.
Yin J; Liu Q; Chen C; Liu W
J Cell Physiol; 2019 Aug; 234(10):17589-17599. PubMed ID: 30825207
[TBL] [Abstract][Full Text] [Related]
53. Cell-surface Vimentin: A mislocalized protein for isolating csVimentin(+) CD133(-) novel stem-like hepatocellular carcinoma cells expressing EMT markers.
Mitra A; Satelli A; Xia X; Cutrera J; Mishra L; Li S
Int J Cancer; 2015 Jul; 137(2):491-6. PubMed ID: 25487874
[TBL] [Abstract][Full Text] [Related]
54. Osteopontin alters DNA methylation through up-regulating DNMT1 and sensitizes CD133+/CD44+ cancer stem cells to 5 azacytidine in hepatocellular carcinoma.
Gao X; Sheng Y; Yang J; Wang C; Zhang R; Zhu Y; Zhang Z; Zhang K; Yan S; Sun H; Wei J; Wang X; Yu X; Zhang Y; Luo Q; Zheng Y; Qiao P; Zhao Y; Dong Q; Qin L
J Exp Clin Cancer Res; 2018 Jul; 37(1):179. PubMed ID: 30064482
[TBL] [Abstract][Full Text] [Related]
55. Overexpression of microRna-200c in CD44+CD133+ CSCS inhibits the cellular migratory and invasion as well as tumorigenicity in mice.
Dou J; He XF; Cao WH; Zhao FS; Wang XY; Liu YR; Wang J
Cell Mol Biol (Noisy-le-grand); 2013 Oct; Suppl 59():OL1861-8. PubMed ID: 24120113
[TBL] [Abstract][Full Text] [Related]
56. LncRNA CASC2 inhibited the viability and induced the apoptosis of hepatocellular carcinoma cells through regulating miR-24-3p.
Fan JC; Zeng F; Le YG; Xin L
J Cell Biochem; 2018 Aug; 119(8):6391-6397. PubMed ID: 29091305
[TBL] [Abstract][Full Text] [Related]
57. Relevant markers of cancer stem cells indicate a poor prognosis in hepatocellular carcinoma patients: a meta-analysis.
Ma YC; Yang JY; Yan LN
Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1007-16. PubMed ID: 23478672
[TBL] [Abstract][Full Text] [Related]
58. Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma.
Tomuleasa C; Soritau O; Rus-Ciuca D; Pop T; Todea D; Mosteanu O; Pintea B; Foris V; Susman S; Kacsó G; Irimie A
J Gastrointestin Liver Dis; 2010 Mar; 19(1):61-7. PubMed ID: 20361077
[TBL] [Abstract][Full Text] [Related]
59. miR-1307-3p promotes tumor growth and metastasis of hepatocellular carcinoma by repressing DAB2 interacting protein.
Chen S; Wang L; Yao B; Liu Q; Guo C
Biomed Pharmacother; 2019 Sep; 117():109055. PubMed ID: 31176165
[TBL] [Abstract][Full Text] [Related]
60. MicroRNA-27a-3p inhibits cell viability and migration through down-regulating DUSP16 in hepatocellular carcinoma.
Li JM; Zhou J; Xu Z; Huang HJ; Chen MJ; Ji JS
J Cell Biochem; 2018 Jul; 119(7):5143-5152. PubMed ID: 29143999
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
